BC Innovations | Jul 25, 2019
Distillery Therapeutics

Phenylisoxazole-quinoline-based DNA gyrase inhibitor for drug-resistant

DISEASE CATEGORY: Infectious disease INDICATION: Staphylococcus A phenylisoxazole-quinoline-based inhibitor of DNA gyrase could treat drug-resistant Staphylococcus aureus infections. In vitro , the compound inhibited S. aureus DNA gyrase supercoiling activity with an IC 50 of 85...
BC Extra | Jun 20, 2019
Company News

Spero's TB program first licensing deal for Gates Medical Research Institute

A partnership to develop Spero's Phase I compound for tuberculosis is the first licensing deal announced by Gates MRI, the translational research institute launched by the Bill & Melinda Gates Foundation in 2017. Spero Therapeutics...
BC Innovations | Feb 11, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus; Streptococcus; Gram-positive bacterial infection In vitro , cell culture, mouse, rat and dog studies identified a spiropyrimidinetrione-based bacterial DNA gyrase inhibitor that could help treat Staphylococcus , Streptococcus and other Gram-positive bacterial infections. Optimization and...
BC Week In Review | Sep 28, 2018
Financial News

Entasis raises $75M in IPO

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) fell $4.34 (29%) to $10.66 on Sept. 26 after it raised $75 million through the sale of 5 million shares at $15 in its IPO. The offering price valued Entasis...
BC Extra | Sep 26, 2018
Financial News

Entasis dips in first trading day after $75M IPO

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) slipped $4.34 (29%) to $10.66 on Wednesday after it raised $75 million through the sale of 5 million shares at $15 in its IPO. The offering price valued Entasis at...
BC Week In Review | Aug 31, 2018
Financial News

Antibacterial company Entasis proposes NASDAQ IPO

Entasis Therapeutics Inc. (Waltham, Mass.) proposed on Aug. 17 to raise $86.3 million in an IPO on NASDAQ underwritten by Credit Suisse, BMO Capital Markets, SunTrust Robinson Humphrey and Wedbush PacGrow. In September, the antibacterial...
BC Extra | Aug 17, 2018
Financial News

Antibacterial company Entasis proposes NASDAQ IPO

Entasis Therapeutics Inc. (Waltham, Mass.) proposed on Friday to raise $86.3 million in an IPO on NASDAQ underwritten by Credit Suisse, BMO Capital Markets, SunTrust Robinson Humphrey and Wedbush PacGrow. In September, the antibacterial company...
BC Week In Review | Apr 6, 2018
Clinical News

Aradigm's Linhaliq under EMA review for lung infection

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights...
BC Extra | Apr 5, 2018
Company News

Aradigm's Linhaliq under EMA review for lung infection

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights...
BC Innovations | Mar 30, 2018
Finance

Bug money

Despite the tremendous public health need and the introduction of regulatory incentives including expedited review and market exclusivity, venture investing in antibiotics remains modest and focused primarily on clinical assets seeking to improve on known...
Items per page:
1 - 10 of 194